×
Taysha Gene Therapies SG&A Expenses 2020-2024 | TSHA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Taysha Gene Therapies sg&a expenses from 2020 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
View More
Taysha Gene Therapies SG&A Expenses 2020-2024 | TSHA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Taysha Gene Therapies sg&a expenses from 2020 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
Related Stocks
Company Name
Market
Cap
Teva Pharmaceutical Industries (TEVA)
$20.1B
Dr Reddy's Laboratories (RDY)
$13.1B
BridgeBio Pharma (BBIO)
$5B
Bausch Health Cos (BHC)
$3B
Amphastar Pharmaceuticals (AMPH)
$2.4B
Supernus Pharmaceuticals (SUPN)
$1.8B
Personalis (PSNL)
$315M
Assembly Biosciences (ASMB)
$117M
Acasti Pharma (ACST)
$28M
Sol-Gel Technologies (SLGL)
$20M
Evoke Pharma (EVOK)
$4M
Teligent (TLGT)
$0M